OncoZenge AB Sustainability Reports
OncoZenge AB is a clinical-stage pharmaceutical company focused on developing innovative treatments for oral pain in cancer supportive care. Its lead product candidate, BupiZenge™, is an oral lozenge formulation providing local pain relief for patients suffering from oral mucositis.
Sector: Manufacturing
Country: Sweden
Exchange: Nasdaq Stockholm
LEI: 2549003980RBCR6NIF38
FIGI: BBG00Y3WQ1S0
2 reports from 2024 to 2025
